Eli Lilly (LLY)

Novo is facing some headwinds, but it has a plan to overcome them.

It was Griffin's biggest add for Citadel last quarter.

The gene-editing biotech stock is down more than 12% this year.

These funds can help you weather any storm that might be on the way.

Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine.

A new government-funded study found that GLP-1 drugs slow the aging process in mice.

The Lilly Foundation is unloading 300,000 shares of the stock.

The stock has soared 25% in six months.

International stock ETFs offer superior diversification, lower valuations, and higher yields than S&P 500 ETFs like VOO.

Even if you add nothing at all, $1,000 can accomplish a lot over decades.

Different categories offer different benefits for investors.

On Oct. 14, 2026, a hotter-than-expected CPI report pressures growth stocks and the semiconductor selloff continues.

It's banking on winners continuing to run.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.

Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.

These stocks have rewarded their shareholders with significant dividend increases in recent years and are likely to continue doing so in the future.

FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but IBB delivered stronger 1-year returns despite higher volatility.

Eli Lilly's next big growth driver could be bigger than Zepbound.

This pharma stock has climbed in the triple digits in recent years.

Eli Lilly's stock price is comfortably above $1,000, and management could easily justify doing a stock split.

AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.